1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

Suggested US Smoking Cessation Roadmap Destinations: Fast Track, Incentives, Indications

 
• By Malcolm Spicer

Potential changes in FDA’s consideration of NRT proposals stated in recent New England Journal of Medicine article by smoking cessation advocates. Cigarettes, “deadliest form of nicotine delivery,” are “subject to limited oversight,” but "products marketed to help people quit smoking face far more substantial regulatory barriers,” they write.

• Source: Shutterstock

Progress toward expanding smoking cessation options in the US and increasing the number of smokers who quit could come from changes in regulatory processes so innovations in nicotine replacement therapies have a better chance for success, advocates suggest.

A roadmap for potential changes in the Food and Drug Administration’s consideration of NRT proposals was provided in a recent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

FDA Proposes Requiring Unit-Dose Packaging For Orally Disintegrating OTC Monograph Drugs

 
• By Malcolm Spicer

Marking most strident use of authorities it received in 2020 as part of an overhaul of monograph system, FDA publishes proposal to shift orally disintegrating formats to individual-dose packaging and a related proposal to minimize firms’ regulatory burden for making delivery format changes potential

Senators’ Questions Stray Far From OMUFA During HELP Committee Hearing On Reauthorization

 
• By Malcolm Spicer

HELP members state frustration with layoffs at FDA and pose questions about topics from generic drug approvals to OTC switches, and from manufacturing location labeling to whether the federal agencies intrude on US consumers. Still, acting CDER director Jacqueline Corrigan-Curay makes clear the resu